PDCD1 and Miyoshi myopathy: In fact, we observed that the fluo-nivolumab bound circulating EVs of MM patients with quite the same efficiency demonstrated in the characterization of PD1+ EVs, both in DPBS and in healthy donors’ EV-depleted plasma.